Recently, Junshi Biosciences announced the establishment of a new wholly-owned subsidiary in Shanghai, a strategic move seen as a key step in deepening its innovative drug development and global expansion. The new company is registered in the Lingang Special Area of the Shanghai Free Trade Zone and will focus on the research, development, and industrialization of cutting-edge biotechnologies, including antibody therapeutics, cell therapy, and gene therapy. As a leading innovation-driven biopharmaceutical company in China, Junshi has consistently increased its R&D investment and actively advanced global clinical trials and partnerships. This new subsidiary will leverage Shanghai’s advantages in supportive biopharma policies, talent concentration, and a robust capital ecosystem, accelerating supply chain integration and collaborative innovation across the Yangtze River Delta region. Additionally, the subsidiary will coordinate certain international multi-center clinical trials, supporting Junshi’s efforts to expand into overseas markets and enhance its global competitiveness. Industry analysts view this move as a clear signal of Junshi’s transition from ‘Chinese innovation’ to ‘global innovation,’ further highlighting Shanghai’s growing appeal as a global hub for biomedical innovation.
近日，君实生物宣布在上海新设一家全资子公司，此举被视为其深化创新药研发与国际化布局的重要战略举措。新公司注册地位于上海自贸区临港新片区，将聚焦于抗体药物、细胞治疗及基因治疗等前沿生物技术领域的研发与产业化。作为中国领先的创新驱动型生物制药企业，君实生物近年来持续加大研发投入，并积极推进全球化临床试验与合作。此次设立子公司，不仅有助于其充分利用上海在生物医药产业政策、人才集聚和资本环境方面的优势，还将加速其在长三角地区的产业链整合与协同创新。此外，新公司将承担部分国际多中心临床试验的协调职能，为君实生物拓展海外市场、提升全球竞争力提供支撑。业内分析认为，这一布局体现了君实生物从‘中国创新’向‘全球创新’转型的决心，也彰显了上海作为全球生物医药创新高地的吸引力。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/18878.html